IPP Bureau
Nova IVF Fertility expands in Kerala with acquisition of Craft Fertility
By IPP Bureau - March 25, 2026
The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1
Novartis strikes $3 billion deal to acquire next-gen breast cancer drug
By IPP Bureau - March 25, 2026
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
Earendil Labs bags $787m to supercharge AI-driven biologics pipeline
By IPP Bureau - March 25, 2026
Capital infusion to accelerate Earendil’s R&D platform
ImmunityBio scores first Asian approval for ANKTIVA in Macau
By IPP Bureau - March 25, 2026
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain
By IPP Bureau - March 25, 2026
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
Roche inaugurates new research home for the Institute of Human Biology
By IPP Bureau - March 24, 2026
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
Japan okays new long-acting eye drug
By IPP Bureau - March 24, 2026
It promises fewer injections for vision loss patients
Bayer wins world-first nod in Japan for low-dose MRI contrast agent
By IPP Bureau - March 24, 2026
Call it a major breakthrough for diagnostic imaging
Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results
By IPP Bureau - March 24, 2026
The company plans to submit the vaccine for regulatory review
Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug
By IPP Bureau - March 24, 2026
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Zydus launches affordable Semaglutide in India after patent expiry
By IPP Bureau - March 23, 2026
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy
By IPP Bureau - March 23, 2026
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
Godavari Biorefineries secures Japanese patent for antiviral compounds
By IPP Bureau - March 23, 2026
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
